Basel, Switzerland

Caspar Vogel

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Binningen, CH (2009)
  • Basel, CH (2017)

Company Filing History:


Years Active: 2009-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Caspar Vogel

Introduction

Caspar Vogel is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds and processes. With a total of 2 patents, Vogel's work has implications in various applications, including pharmaceuticals.

Latest Patents

Vogel's latest patents include a process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester. This invention relates to novel processes for synthesizing this compound and other intermediates used in such processes. Another significant patent is for the preparation of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1H)-quinolin-2-one salt, which is useful as an andrenoceptor agonist. This process involves forming an acid salt and converting it to a salt of the desired compound without isolating the free base.

Career Highlights

Caspar Vogel is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in the pharmaceutical industry. His contributions have been instrumental in advancing research and development in his field.

Collaborations

Vogel has collaborated with notable colleagues such as Olivier Lohse and Fabrice Gallou. These collaborations have fostered a productive environment for innovation and have led to the successful development of new chemical processes.

Conclusion

Caspar Vogel's inventive spirit and dedication to research have led to significant advancements in chemical synthesis. His patents reflect a commitment to innovation that continues to impact the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…